Where Discovery Begins
Free Shipping for In-Stock Functional Cell Line
More>
Leave Your Comment & Get 20% Off
More>
Share Your Cell Line Experience. Get Rewarded.
More>
Contact Us
Home
/ / / / / /
EN
CN
EN
CN
Search
Home
Products
Products
Cell Lines
Cell Lines
Antibody Related
Cell Tracing
Cytokines
GPCR
Immune Checkpoint
Immunology
In Vivo Imaging
Kinase
Metabolism
Molecular-Reference-Standards
Nuclear Receptors
PRR Signalings
Pseudovirus
TLR
TNF Superfamily
Transcription Factor
Tumor-Associated Antigen(TAA)
Others
Proteins
Proteins
ADC Internalization
Antibody Related
Cytokines
GPCR
Immune Checkpoint
Immunology
Kinase
Metabolism
Others
PRR signalings
Tumor-Associated Antigen(TAA)
TNF Superfamily
Antibodies
Antibodies
Biosimilar Antibodies
Biosimilar Antibodies
Cytokines
GPCR
Immune Checkpoint
Immunology
Kinase
Metabolism
multispecific antibodies
PRR signalings
Pseudovirus
TNF Superfamily
Tumor-Associated Antigen(TAA)
Others
ADC Antibodies
ADC Antibodies
ADC Biosimilar Antibodies
ADC Isotype Antibodies
ADC Related Antibodies
Anti-payload Antibodies
In Vivo MAb Antibodies
In Vivo MAb Antibodies
Functional Antibodies
Isotype Controls
Virus neutralizing antibodies
Antibody Related
Tag Antibodies/Loading Controls Antibodies
Services
Services
Cell Line Development
Cell Line Commercial Licensing & Compliance Support
Cell-based Assay
Reporter Gene Assay
Protein Expression
Antibody Expression
Activity
News
Genomeditech
Cell Line Development
Cell Line Commercial Licensing & Compliance Support
Cell-based Assay
Reporter Gene Assay
Protein Expression
Antibody Expression
Current position：Technical Service > Cell-based Assay
Cell-based Assay
Introduction
Genomeditech' s Cell-Based Assay Platform provides integrated solutions for functional evaluation of biologics and therapeutic molecules, from assay development and optimization to quantitative functional assessment. Supported by proprietary engineered cell libraries and advanced cell engineering capabilities, the platform offers broad target coverage and flexible assay formats for diverse research needs.

 

400+ Engineered Cell Lines    2,000+ Stable Cell Lines    300+ Reporter Cell Lines

60+ Host Cells    1000+ Assay Projects

 

 

Cell-based Assay Capabilities
Reporter Gene Assay
Quantitative evaluation of target activation, inhibition, pathway signaling, and functional activity.
Effector Function Bioassay (ADCC / ADCP)
Functional assessment of antibody-mediated immune effector activity.
Cell Proliferation & Cytotoxicity
Evaluation of drug-induced cellular proliferation, viability, and cytotoxic responses.
Target-Specific Functional Assay
Mechanism-relevant functional assays designed around specific targets and biological pathways.
Custom Assay Development
Fit-for-purpose assay development tailored to molecule format, mechanism of action, target biology, and evaluation requirements.
 

A comprehensive collection of engineered cell models covering diverse therapeutic targets, signaling pathways, and immune functions, providing a robust foundation for cell-based assay development.

Service Process
Key Advantages

Reproducible Results

Engineered clonal stable cell lines minimize donor variability and batch-to-batch variation for consistent results.

 

Highly Sensitive Quantification

Luciferase reporters provide signal amplification and a broad dynamic range for sensitive potency assessment.

 

Wide Assay Window & Comparable Readouts

Low background and million-level RLU signals enable robust signal separation and cross-batch data comparison.

 

Compliance & Traceability

Commercial use authorization for key cell lines, including HEK293, Jurkat E6.1, and CHO-K1, with traceability documentation available.

Case Study 1 | ADC / Fc-Engineered Antibodies

Quantitative ADCC Effector Function Assessment

 

GM-C05619 FcγRIIIa (158V) Reporter Jurkat

Stable expression of FcγRIIIa and NFAT-Luc enables quantitative assessment of antibody-dependent cellular cytotoxicity (ADCC).

 

Wide Assay Window | EC50 Quantification | Comparative Potency Assessment

Supports functional assessment of ADCC, ADCP, CDC, and internalization for ADC and Fc-engineered antibody candidates.

 

Case Study 2 | Tumor-Targeting Bispecific Antibodies

CTLA-4 / PD-1 Dual-Pathway Blockade Activity

 

GM-C26486 H_CTLA4 PD-1 Reporter + GM-C30574 H_CD80 PDL1 aAPC CHO-K1

Paired reporter and aAPC cells enable quantitative assessment of immune checkpoint blockade activity in monoclonal antibodies, bispecific antibodies, and combination treatments.

 

Low Background | Wide Assay Window | EC50 Quantification

Supports multi-pathway immune checkpoint evaluation and functional characterization of T-cell engager (TCE) molecules.

 

Case Study 3 | Conditional Immune Agonists

Functional Evaluation of PD-1–IL-2v Fusion Proteins

 

GM-C41979 H_CD25 CD122 CD132 PD1 Reporter Jurkat

Co-expression of PD-1 and the complete IL-2 receptor complex enables evaluation of PD-1-dependent immune activation.

 

Low Background | Target-Specific Validation | EC50 Quantification

A PD-1-negative parental control enables differentiation between target-dependent and nonspecific activation.

 

Case Study 4 | Autoimmune / Inflammatory Drug Candidates

DR3 / TL1A Pathway Antagonist Activity Assessment

 

GM-C30290 H_TNFRSF25 (DR3) Reporter Jurkat

Stable expression of DR3 and a luciferase reporter enables both agonist activity screening and antagonist blockade assessment in a single cell model.

 

Wide Assay Window | IC50 Quantification | High Inter-Batch Reproducibility

Supports functional characterization of agonists and antagonists targeting OX40/OX40L, TSLP, TL1A/DR3, and other immune signaling pathways.

 

Case Study 5 | Weight Management / Metabolic Drug Candidates

Multi-Target GPCR Agonist Activity Assessment

 

GM-C25536 H_GIPR Reporter CHO-K1

Stable expression of GIPR and CRE-Luc enables quantitative assessment of GPCR-mediated receptor activation.

 

Wide Assay Window | EC50 Quantification | Comparative Receptor Activation

Enables potency and selectivity profiling of single, dual, and triple agonists targeting GLP-1R, GIPR, and GCGR.

 

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Current position：Technical Service > Cell-based Assay
classify
Cell-based Assay
Introduction
Genomeditech' s Cell-Based Assay Platform provides integrated solutions for functional evaluation of biologics and therapeutic molecules, from assay development and optimization to quantitative functional assessment. Supported by proprietary engineered cell libraries and advanced cell engineering capabilities, the platform offers broad target coverage and flexible assay formats for diverse research needs.

 

400+ Engineered Cell Lines    2,000+ Stable Cell Lines    300+ Reporter Cell Lines

60+ Host Cells    1000+ Assay Projects

 

 

Cell-based Assay Capabilities
Reporter Gene Assay
Quantitative evaluation of target activation, inhibition, pathway signaling, and functional activity.
Effector Function Bioassay (ADCC / ADCP)
Functional assessment of antibody-mediated immune effector activity.
Cell Proliferation & Cytotoxicity
Evaluation of drug-induced cellular proliferation, viability, and cytotoxic responses.
Target-Specific Functional Assay
Mechanism-relevant functional assays designed around specific targets and biological pathways.
Custom Assay Development
Fit-for-purpose assay development tailored to molecule format, mechanism of action, target biology, and evaluation requirements.
 

A comprehensive collection of engineered cell models covering diverse therapeutic targets, signaling pathways, and immune functions, providing a robust foundation for cell-based assay development.

Service Process
Key Advantages

Reproducible Results

Engineered clonal stable cell lines minimize donor variability and batch-to-batch variation for consistent results.

 

Highly Sensitive Quantification

Luciferase reporters provide signal amplification and a broad dynamic range for sensitive potency assessment.

 

Wide Assay Window & Comparable Readouts

Low background and million-level RLU signals enable robust signal separation and cross-batch data comparison.

 

Compliance & Traceability

Commercial use authorization for key cell lines, including HEK293, Jurkat E6.1, and CHO-K1, with traceability documentation available.

Case Study 1 | ADC / Fc-Engineered Antibodies

Quantitative ADCC Effector Function Assessment

 

GM-C05619 FcγRIIIa (158V) Reporter Jurkat

Stable expression of FcγRIIIa and NFAT-Luc enables quantitative assessment of antibody-dependent cellular cytotoxicity (ADCC).

 

Wide Assay Window | EC50 Quantification | Comparative Potency Assessment

Supports functional assessment of ADCC, ADCP, CDC, and internalization for ADC and Fc-engineered antibody candidates.

 

Case Study 2 | Tumor-Targeting Bispecific Antibodies

CTLA-4 / PD-1 Dual-Pathway Blockade Activity

 

GM-C26486 H_CTLA4 PD-1 Reporter + GM-C30574 H_CD80 PDL1 aAPC CHO-K1

Paired reporter and aAPC cells enable quantitative assessment of immune checkpoint blockade activity in monoclonal antibodies, bispecific antibodies, and combination treatments.

 

Low Background | Wide Assay Window | EC50 Quantification

Supports multi-pathway immune checkpoint evaluation and functional characterization of T-cell engager (TCE) molecules.

 

Case Study 3 | Conditional Immune Agonists

Functional Evaluation of PD-1–IL-2v Fusion Proteins

 

GM-C41979 H_CD25 CD122 CD132 PD1 Reporter Jurkat

Co-expression of PD-1 and the complete IL-2 receptor complex enables evaluation of PD-1-dependent immune activation.

 

Low Background | Target-Specific Validation | EC50 Quantification

A PD-1-negative parental control enables differentiation between target-dependent and nonspecific activation.

 

Case Study 4 | Autoimmune / Inflammatory Drug Candidates

DR3 / TL1A Pathway Antagonist Activity Assessment

 

GM-C30290 H_TNFRSF25 (DR3) Reporter Jurkat

Stable expression of DR3 and a luciferase reporter enables both agonist activity screening and antagonist blockade assessment in a single cell model.

 

Wide Assay Window | IC50 Quantification | High Inter-Batch Reproducibility

Supports functional characterization of agonists and antagonists targeting OX40/OX40L, TSLP, TL1A/DR3, and other immune signaling pathways.

 

Case Study 5 | Weight Management / Metabolic Drug Candidates

Multi-Target GPCR Agonist Activity Assessment

 

GM-C25536 H_GIPR Reporter CHO-K1

Stable expression of GIPR and CRE-Luc enables quantitative assessment of GPCR-mediated receptor activation.

 

Wide Assay Window | EC50 Quantification | Comparative Receptor Activation

Enables potency and selectivity profiling of single, dual, and triple agonists targeting GLP-1R, GIPR, and GCGR.

 

Cell Line Development
Cell Line Commercial Licensing & Compliance Support
Cell-based Assay
Reporter Gene Assay
Protein Expression
Antibody Expression
Products
Cell Lines Proteins Antibodies Lentivirus Adeno-Associated Virus (AAV) Plasmid Molecular Reference Standards Pseudovirus control material Pseudovirus Reporter gene detection-related reagents Reagents related to cell function detection and analysis Genoagent (Brand name of reagents)
Services
Cell Line Development Cell Line Commercial Licensing & Compliance Support Cell-based Assay Reporter Gene Assay Protein Expression Antibody Expression
Resource
Citations Database Handbook Product Manual Query
Genomeditech
About History Honor Contact Careers
Social Media
Linkedin
Twitter
Partner Platform
Scientist
Toll-free hotline：400-627-9288
Email address：mkt.genomeditech@gmail.com
Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai
Message Inquiry
Submit
Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.
Privacy Policy
Contact
Us
Message Inquiry
reset
submit
Toll-free hotline：400-627-9288
Email address：mkt.genomeditech@gmail.com
Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai
Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.
Message
Message Inquiry
reset
submit